#melanoma

Immunotherapy Combo Improves Melanoma That Has Spread to Brain

Chelsea Dawson, an eight-year melanoma survivor, lives with her family in Roanoke, Virginia.

Several studies focused on this topic were recently reported on at the AACR-Melanoma Conference.

Although more than 400 melanoma-focused clinical trials are recruiting participants, 1 out of 3 of them will fail due to low enrollment.

When taken together, the results of the study indicate that being female is a risk factor for early-onset melanoma.

Among young people, rates of melanoma are especially alarming; it is now the second most-common cancer among young women aged 20–29.

As more patients respond well to these emerging therapies, the rules for treating late-stage patients will need to be rewritten.

New, more effective and better tolerated options make doctors’ decision to recommend adjuvant therapy—and patients’ to start it—easier...

“I’m so impressed by the brilliance and dedication of the researchers and doctors in this field,” says MRA co-founder Debra Black.

New treatments for melanoma approved over the last decade appear to be improving survival and reducing mortality rates.

Allison’s work helped to reinvigorate and mainstream the field of immunotherapy.

The approach, called an implantable cancer treatment vaccine, is being tested in a small phase 1 clinical trial.

“Melanoma research is leading the way, and that energy and momentum is driving all of oncology forward. It’s a very exciting time.”

MRA’s 2017–2018 Annual Report

Today, there are more than 15 million cancer survivors in the United States. How do we support them? What do they need?